An Intervention Study to Improve Therapeutic Compliance in Adult Patients With Eosinophilic Esophagitis.
Launched by ACADEMISCH MEDISCH CENTRUM - UNIVERSITEIT VAN AMSTERDAM (AMC-UVA) · Feb 15, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying ways to help adults with eosinophilic esophagitis (EoE) stick to their treatment plans. EoE is a condition where too many eosinophils, a type of white blood cell, build up in the esophagus, leading to symptoms like difficulty swallowing and pain. Many patients struggle to follow their prescribed treatments over the long term, so the researchers want to see if giving more education, regular follow-ups, and reminders can encourage better adherence to treatment.
To participate in this trial, you need to be an adult over 18 years old who has been diagnosed with EoE through a biopsy, and you should be currently receiving or about to start maintenance treatment, such as medications that help reduce inflammation. If you have other serious health issues, are receiving another investigational treatment, or need a procedure to widen your esophagus, you won't be eligible for this study. Participants will receive additional support and information throughout the trial to help them manage their condition more effectively.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Written informed consent
- • Male or female patient
- • Age \>18 years
- • Previous diagnosis of EoE, confirmed by histopathology, with the presence of \>15 eosinophilic granulocytes per high power field (hpf) in esophageal biopsies
- • Current maintenance treatment for EoE with a PPI or swallowed topical corticosteroids or about to start with these maintenance medications as decided during regular clinical practice
- Exclusion Criteria:
- • Severe and clinically unstable concomitant disease that may interfere with the subject's ability to participate in the study
- • Receive investigational treatment during the study
- • Dilation of esophagus required
- • Insufficient Dutch or English language skills to understand patient information leaflets
About Academisch Medisch Centrum Universiteit Van Amsterdam (Amc Uva)
The Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) is a leading academic medical center in the Netherlands, dedicated to advancing healthcare through innovative research, education, and patient care. Affiliated with the University of Amsterdam, AMC-UvA integrates clinical practice with cutting-edge biomedical research, fostering a multidisciplinary approach to medical challenges. The institution actively engages in clinical trials to enhance treatment options and improve patient outcomes, while promoting collaboration among healthcare professionals, researchers, and academic institutions globally. With a commitment to excellence and a focus on translational medicine, AMC-UvA plays a pivotal role in shaping the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Amsterdam, Noord Holland, Netherlands
Amsterdam, Noord Holland, Netherlands
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials